• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Phillips Anne M.

    6/12/25 4:26:08 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTVT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Phillips Anne M.

    (Last) (First) (Middle)
    C/O VTV THERAPEUTICS INC.
    3980 PREMIER DRIVE, SUITE 310

    (Street)
    HIGH POINT NC 27265

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    vTv Therapeutics Inc. [ VTVT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/10/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Director stock option (right to buy) $16.59 06/10/2025 A 4,000 (1) 06/10/2035 Class A Common Stock 4,000 $16.59 10,860 D
    Explanation of Responses:
    1. The option vests on the earlier of June 10, 2026, and the date of the 2026 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting.
    Remarks:
    /s/ Elizabeth Keiley, as Attorney-in-fact 06/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VTVT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTVT

    DatePrice TargetRatingAnalyst
    2/18/2022$5.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $VTVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres, CEO and Exec Chairperson Sekhri Paul J bought $83,812 worth of shares (5,000 units at $16.76) (SEC Form 4)

    4 - vTv Therapeutics Inc. (0001641489) (Issuer)

    11/19/24 4:31:06 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on vTv Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of vTv Therapeutics with a rating of Overweight and set a new price target of $5.00

    2/18/22 6:42:27 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTVT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    •   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 •   Cadisegliatin intellectual property portfolio expanded •   Leadership team strengthened HIGH POINT, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent corporate developments. "The

    8/12/25 4:15:00 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

    HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application directed to compositions of matter of crystalline forms of salts and co-crystals of cadisegliatin. The patent term runs through 2041. "We are pleased with the outcome of the prosecution of this patent as it further strengthens the protection around cadisegliatin," s

    8/11/25 8:00:00 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

    HIGH POINT, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced the first study participant has been randomized in the Company's CATT1 Phase 3 trial investigating cadisegliatin as an adjunctive treatment to insulin in adults with type 1 diabetes (T1D). Cadisegliatin is a potential first-in-class, oral, liver-selective glucokinase activator for T1D that has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) and has been well-tolerated in over 500 subjects to date with up to six months

    8/7/25 8:00:00 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Baker Bros. Advisors Lp

    4 - vTv Therapeutics Inc. (0001641489) (Issuer)

    6/12/25 4:28:34 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Spiegelman Daniel K

    4 - vTv Therapeutics Inc. (0001641489) (Issuer)

    6/12/25 4:28:17 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Akkaraju Srinivas

    4 - vTv Therapeutics Inc. (0001641489) (Issuer)

    6/12/25 4:27:28 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTVT
    SEC Filings

    View All

    SEC Form 10-Q filed by vTv Therapeutics Inc.

    10-Q - vTv Therapeutics Inc. (0001641489) (Filer)

    8/12/25 4:09:52 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - vTv Therapeutics Inc. (0001641489) (Filer)

    8/12/25 4:05:11 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - vTv Therapeutics Inc. (0001641489) (Filer)

    6/12/25 4:23:03 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTVT
    Leadership Updates

    Live Leadership Updates

    View All

    vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    •   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 •   Cadisegliatin intellectual property portfolio expanded •   Leadership team strengthened HIGH POINT, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent corporate developments. "The

    8/12/25 4:15:00 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

    HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical industry. This executive appointment comes at an important time for the Company, which recently reinitiated screening in its CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of

    5/19/25 9:00:00 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

    Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2024, and provided an update on recent corporate de

    3/20/25 5:35:31 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by vTv Therapeutics Inc.

    SC 13G - vTv Therapeutics Inc. (0001641489) (Subject)

    11/12/24 10:40:28 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by vTv Therapeutics Inc. (Amendment)

    SC 13D/A - vTv Therapeutics Inc. (0001641489) (Subject)

    3/22/24 4:57:31 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by vTv Therapeutics Inc.

    SC 13D - vTv Therapeutics Inc. (0001641489) (Subject)

    3/5/24 7:52:29 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTVT
    Financials

    Live finance-specific insights

    View All

    vTv Therapeutics Announces Investment by CinRx Pharma

    HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC ("CinPax"), a subsidiary of CinRx Pharma, LLC ("CinRx"). Under the terms of the agreements, CinPax acquired 4,154,549 shares of Class A Common Stock of vTv at an issue price of approximately $2.41 per share, with $6 million paid in cash at closing, and the remaining amount of $4 million payable on November 22, 2022. The agreements also provide for the issuance of 1.2 million warrants to CinRx to acquire additional shares of Class A Common Stock that become exercisable upon agreed vesting triggers (including FDA ap

    7/25/22 7:00:00 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care